License
RSS

Alteogen names MSD as partner in revised, potential $3.8B+ deal

Feb. 27, 2024

In a surprise reveal that propelled stocks by 25%, Alteogen Inc., of Daejeon, South Korea, named MSD International Business GmbH as its counterpart in a near-$4 billion technology transfer agreement inked in 2020, while upping terms of the deal.

Alteogen names MSD as partner in revised, potential $3.8B+ deal

Feb. 23, 2024

By Marian (YoonJee) Chu

Kyowa pays $100M up front for Bridgebio’s infigratinib in Japan

Feb. 20, 2024

By Marian (YoonJee) Chu

Palo Alto, Calif.-based Bridgebio Pharma Inc. will hand over development and sales of its rare bone growth disorder therapy, infigratinib, in Japan to Kyowa Kirin Co. Ltd. under its latest exclusive licensing deal.

Dermatologic

Almirall to study Novo Nordisk’s anti-IL-21 monoclonal antibody for derma indications

Feb. 19, 2024

Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk A/S for global rights to develop and commercialize the IL-21-blocking monoclonal antibody NN-8828 in certain fields, including immune inflammatory dermatological diseases.

Drug Design, Drug Delivery & Technologies

GSK to use Elsie’s platform for oligonucleotide drug discovery

Feb. 15, 2024

GSK plc has exercised its option to a nonexclusive license to Elsie Biotechnologies Inc.’s discovery platform, following a successful research collaboration both companies entered into last year to explore platform capabilities.

Drug Design, Drug Delivery & Technologies

Delsitech and Tolmar sign agreement for use of silica matrix drug delivery platform

Feb. 13, 2024

Delsitech Ltd. and Tolmar International Ltd. have signed a global license and development agreement whereby Tolmar will obtain a global license to utilize Delsitech’s proprietary, silica-based, drug delivery technology platform for the development and commercialization of two undisclosed long-acting injectable drug products.

Kyowa pays $100M up front for Bridgebio’s infigratinib in Japan

Feb. 8, 2024

By Marian (YoonJee) Chu

Neurology/Psychiatric

Vect-Horus signs license agreement with Ionis to support work in neurological disease

Jan. 31, 2024

Vect-Horus SAS has entered into a license agreement providing Ionis Pharmaceuticals Inc. with a worldwide, exclusive license for a specified number of targets using Vect-Horus’ platform technology Vectrans for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier and address targets in the central nervous system.

Cancer

Harmonic Discovery licenses kinase inhibitor for FLT3-mutated AML from Bioventures and UCSF

Jan. 31, 2024

Harmonic Discovery Inc. has entered into an exclusive licensing agreement for a small-molecule drug candidate for the treatment of FLT3-mutated acute myeloid leukemia (AML) from Bioventures (University of Arkansas for Medical Sciences) and University of California San Francisco (UCSF).

Travere licenses out rare kidney disease drug to Renalys in Asia

Jan. 30, 2024

By Marian (YoonJee) Chu

Travere Therapeutics Inc. inked a licensing deal with Tokyo-based Renalys Pharma Inc. to develop sparsentan in 13 Asian countries, becoming the latest news to heat up the immunoglobulin A nephropathy (IgAN) therapy space.

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

License RSS

License
RSS